Please login to the form below

Not currently logged in
Email:
Password:

tenofovir disproxil

This page shows the latest tenofovir disproxil news and features for those working in and with pharma, biotech and healthcare.

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’and ‘durable’viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

Latest news

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The EMA advisors issued a positive opinion for Vemlidy (tenofovir alafenamide) after data from two phase III studies showed Vemlidy to be superior to its predecessor Viread (tenofovir disproxil) in both

  • Research in HIV therapies Research in HIV therapies

    America. Tenofovir alafenamide (GS 7340) and tenofovir disproxil fumarate (TDF, Viread) are two prodrugs developed by Gilead and designed to have better oral availability and adverse events profiles than tenofovir. ... Tenofovir (Gilead, CONRAD) is a

  • Gilead wins over IQWiG with new Eviplera data Gilead wins over IQWiG with new Eviplera data

    There is now proof that also in the fixed combination with emtricitabine and tenofovir disoproxil, rilpivirine offers a considerable added benefit for men infected with HIV-1. ... Eviplera combines Tibotec and Johnson &Johnson's Edurant (rilpivirine)

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics